Case File
efta-efta00965007DOJ Data Set 9OtherFrom: Jeffrey Epstein <jeevacation®gmail.com>
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00965007
Pages
2
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Jeffrey Epstein <jeevacation®gmail.com>
To: '
Subject: Fwd: amyloid increases homocysteic acid toxicity
Date: Wed, 17 Jul 2013 09:20:13 +0000
Forwarded message
From:
Date: Tuesday, July 16, 2013
Subject: Fwd: amyloid increases homocysteic acid toxicity
To: Jeffrey Epstein <[email protected]>
Forwarded message
From: Tohru
Date: Tue, Jul 16, 2013 at 7:00 PM
Suliect: amyloid increases homocysteic acid toxicity
To:
Dear Christina;
I am afraid Jeffrey has a question about the relationship between amyloid beta and homocysteic acid in
blood for Alzheimer's disease process.
Amyloid hypothesis is still valid for preventing AD. We already observed that homocysteic acid toxicity,
especially, neurodegenerative toxicity, will increase in the presence of amyloid.
However it has been observed that amyloid protein is present in normal brain, which shows that amyloid
itself has no toxicity for brain work.
Homocysteic acid has the original pathogen for AD process. Early onset of AD, familial AD, has higher
production of amyloid, which increases the homocysteic acid toxicity, then very lower level of homocysteic
acid can start the disease process. Recent reports indicate that ApoE4 increases the permeability of blood
brain barrier, which allows the invasion of lower level of homocysteic acid in blood into brain.
This my hypothesis is strongly supported by my TSH1 recovery, because TSH1 decreased homocysteic acid
level in blood and blocked homocysteic acid toxicity in brain.
EFTA00965007
Now I am sincerely request your support.
Sincerely yours
Tohru
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA00965008
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.